Molecular Partners (NASDAQ:MOLN) Issues Earnings Results

Molecular Partners (NASDAQ:MOLN) announced its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.02, FiscalAI reports.

Molecular Partners Stock Performance

Shares of MOLN opened at $4.40 on Tuesday. The firm has a market capitalization of $177.65 million, a P/E ratio of -2.27 and a beta of 1.08. Molecular Partners has a 52 week low of $3.53 and a 52 week high of $5.36. The stock has a 50 day moving average price of $4.03 and a two-hundred day moving average price of $4.23.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. HC Wainwright reaffirmed a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.38.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.